The 22nd JFCR-ISCC

New Antitumor Agents
under Developmentin the US, Europeand Japan
Miraikan(Wed) 13:00 -19:00
December13
2017 December 14 (Thu) 9:00 -18:30

National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Dec. 13（Wed）
Session 1 Genetic biomarkers andScott K. Pruitt Merck Research Laboratories
The first tumor-type agnostic regulatory approval:
13:10 Pembrolizumab for the treatment of advanced
rational combinations for
MSI-H/dMMR cancer
cancer immunotherapy
Philip J. Stephens Foundation Medicine

Identification of novel modulators of response to immune
checkpoint blockade in lung cancer patients throughthe marrying of clinical and genomic data

Session 2
15:00 16:20 17:20 -G. Pommier NCI, NIH
Sophisticated DNA damage Yves
PARP trapping and replicative damages
inducers for cancer therapy Hiroki Nagase Chiba Cancer Ctr. Res. Inst.
Poster Flash Talks
Poster Session & Mixer

Targeting the Achilles’ heel of cancer: Sequence specificalkylation at KRAS driver gene DNA mutations

Dec. 14（Thu）
Session 3 New technologies and drugs Pablo Umaña Roche Glycart AG
CEA-TCB: A novel bispecific antibody targeting solid tumors
9:00 under clinical or preclinical Antoine Yver Daiichi-Sankyo
Clinical study results of DS-8201a, a novel HER2-targetinginvestigations
ADC with a DNA topoisomerase I inhibitor
Lothar Finke Incyte Biosciences Japan

11:30 -

Poster Discussion Session

12:20 -Luncheon Seminar

Session 4
13:30 -

14:50 -Session 5
16:20 -

Targeting IDO1 in the TME: A novel approach to combination
immunotherapy for cancer
River Discovery ResearchThomas Metz CharlesServices GmbH

Preclinical in vivo profiling of i/o and non i/o anti-cancer agents:
Optimization of model selection

Schile Jackson Laboratory
Drug discovery and preclinical Andrew“Onco-Hu” mouse model for evaluating immuno-oncology
evaluation using cellular and therapeutics
Masahiro Inoue Osaka Int. Cancer Inst.
patient-derived models
Drug screening by use of a panel of primary cultured
Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas"Integrated Analysis and Regulation of Cellular Diversity (4904)"cancer spheroids derived from clinical tumor samples

Special Lecture

Bruce A. Chabner MGH / Harvard Med. Sch.
Challenges and opportunities for targeted therapies

D. Car BMS
Next generation of combination Bruce
Overview of IO drug development
cancer immunotherapy
Michael Axelson BMS
Supported byOverview of Immuno-Oncology clinical development forcombinations of checkpoint inhibitors

Inst., EPOC, NCC/
Hiroyoshi Nishikawa Res.
Nagoya Univ.

Genome-immune analyses to decipher anti-tumor immune responses
Contact : Cancer Chemotherapy Center, Japanese Foundation for Cancer Researchjfcr-iscc@ml.jfcr.or.jp

http://iscc.umin.jp/

The 22nd JFCR-ISCC is supported by following companies: Bristol-Myers Squibb K.K., Kyowa Hakko Kirin Co., Ltd., Taiho Pharmaceutical Co., Ltd., AbbVie Inc., Biogen Japan Ltd.,Celgene K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., FUJIFILM Corporation, Meiji Seika Pharma Co., Ltd., MSD K.K., Ono Pharmaceutical Co., Ltd.,Sanofi K.K., Sysmex Corporation, Yakult Honsha Co., Ltd., Zenyaku Kogyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and Novartis Pharma K.K.